Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the cholesterol biosynthetic pathway in a keratinocyte model for esophageal irritation

Molecular Pharmacology

Volumn 59, Issue 2, 2001, Pages 193-202

  Reszka, Alfred A ^a   Halasy Nagy, Judit ^a   Rodan, Gideon A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; MEVINOLIN; NITROGEN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE S PHASE; CELL GROWTH; CHOLESTEROL SYNTHESIS; CYTOKINESIS; ENZYME INHIBITION; EPITHELIUM CELL; ESOPHAGUS MUCOSA; GROWTH INHIBITION; KERATINOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR BLOCKING; RETINOBLASTOMA; SQUAMOUS EPITHELIUM;

EID: 0035135687     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.59.2.193     Document Type: Article

References (36)

1. WAF1/CIP1 is upregulated by the geranylgeranyltransferase I inhibitor GGTI-298 through a transforming growth factor β- and Sp1-responsive element: Involvement of the small GTPase RhoA
2. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis
3. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates
4. SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box
5. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: Biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs
6. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase
7. Nonclinical model for assessing gastric effects of bisphosphonates
8. Exogenous and endogenous sources of sterols in the culture-adapted procyclic trypomastigotes of Trypanosoma brucei
9. Esophagitis associated with the use of alendronate
10. Alendronate induces gastric injury and delays ulcer healing in rodents
11. Cholesterol synthesis is required for cutaneous barrier function in mice
12. The lovastatin-treated rodent: A new model of barrier disruption and epidermal hyperplasia
13. Alendronate mechanism of action: Geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro
14. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo
15. waf1/cip1 in human prostate carcinoma cells
16. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras
17. Platelet-derived growth factor receptor tyrosine phosphorylation requires protein geranylgeranylation but not farnesylation
18. Structural basis for the barrier abnormality following inhibition of HMG CoA reductase in murine epidermis
19. Competitive inhibition of choline phosphotransferase by geranylgeraniol and farnesol inhibits phosphatidylcholine synthesis and induces apoptosis in human lung adenocarcinoma A549 cells
20. Lovastatin inhibits G1/S transition of normal human B-lymphocytes independent of apoptesis
21. Esophageal irritation due to alendronate sodium tablets: Possible mechanisms
22. Comparative study of potential for bisphosphonates to damage gastric mucosa of rats
23. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53
24. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase
25. Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptesis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase
26. The bisphosphonate incadronate (YM175) causes apoptesis of human myeloma cells in vitro by inhibiting the mevalonate pathway
27. Bisphosphonates induce apoptosis in human myeloma cell lines: A novel anti-tumour activity
28. The geranylgeranyltransferase I inhibitor GGTI-298 induces hypophosphorylation of reti noblastoma and partner switching of cyclin-dependent kinase inhibitors. A potential mechanism for GGTI-298 antitumor activity
29. Efficacy and long-term adverse effect pattern of lovastatin
30. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogencontaining bisphosphonates
31. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates
32. WAF1/CIP1/SDI1 in a p53-independent manner
33. Protein geranylgeranylation, not farnesylation, is required for the G1 to S phase transition in mouse fibroblasts
34. Nbisphosphonates cause gastric epithelial injury independent of effects on the microcircuiation
35. N-arylpiperazinone inhibitors of farnesyltransferase: Discovery and biological activity
36. Human CUL-1 associates with the SKP1/ SKP2 complex and regulates p21(CIP1/WAF1) and cyclin D proteins